Why Is NEOGEN CORP (NEOG) Stock Up Today?

NEOG stock surged 19.64% to $11.24 in a volatile session driven by Neogen's strong fourth-quarter earnings report and upbeat guidance for fiscal 2027. The company reported revenue of $225.3 million for Q4, with core revenue growth of 4.3%, the highest of fiscal 2026. Neogen also outlined FY 2027 revenue guidance of $880 million to $885 million and adjusted EBITDA of $180 million to $182 million, despite a 50% increase in R&D spending.

What Happened

The stock opened with a 1.8% gap up and quickly climbed to a session high of $11.24. The company's Q4 earnings call highlighted improved momentum in both its food safety and animal health segments. The CEO and President, Mikhael Nassif, emphasized accelerating core growth and the strategic divestiture of its genomics business. The 8-K filing disclosed preliminary results of operations and included financial statements, reinforcing the company’s performance. Neogen also reported adjusted EPS of $0.09, exceeding the estimated loss of $0.07, and sales of $225.3 million, surpassing the $212.355 million estimate.

What The Data Shows

The intraday session saw heavy volume of 1.8 million shares, nearly 80% above the 3-month average. The stock traded within a wide range from $9.57 to $11.24, peaking at 1:40 PM ET. Neogen’s market cap currently stands at $2.0 billion, with a trailing twelve-month revenue decline of 3.9% and a net margin of -69.9%. The stock remains unprofitable, with a TTM EPS of -2.80. The 52-week range is $4.56 to $11.43, suggesting the stock is near its recent high.

What To Watch

Neogen’s Q1 sales guidance of $207 million to $209 million is set to be a key focus in the coming weeks. Investors should also monitor the regulatory status of Zoetis’ acquisition of Neogen’s genomics business, particularly in Australia. Coverage breadth and any follow-up analyst commentary will be important to watch as the market digests the company’s long-term growth strategy.